Global Acromegaly and Gigantism Drugs Market 2018-2022
- Published: Feb 2018
- Pages: 100
- SKU: IRTNTR20504
The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!
The global acromegaly and gigantism drugs market size will grow by USD 189.78 million during 2018-2022. This report offers an analysis of the market based on drug class (somatostatin analogs, GH receptor antagonists, dopamine agonists, recombinant human IGF-1) and geography (the Americas, APAC, and EMEA). The acromegaly and gigantism drugs market research report further analyzes the market’s competitive landscape and offers information on several companies including Ipsen, Novartis, and Pfizer.
Below are some of the key findings from the acromegaly and gigantism drugs market research report
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Get a FREE sample now!
Global acromegaly and gigantism drugs industry overview
The presence of a strong pipeline will be one of the primary factors driving the acromegaly and gigantism drugs market growth until 2022. Researchers are focusing on launching pipeline molecules for acromegaly and gigantism and most of these molecules are in the Phase III stage of development. The availability of a large number of molecules in the pipeline is resulting in increased consumption of gigantism and acromegaly drugs. Numerous companies are trying to meet the medical needs for this condition by focusing more on drug development. Pasireotide long-acting release (LAR) by Novartis and octreotide capsules by Chiasma are in the Phase III stage of development for the treatment of acromegaly. They are targeted at individuals with acromegaly who are inadequately treated with the combination therapy of lanreotide autogel and pegvisomant by Ipsen and somatostatin analogs. This, in turn, results in a strong pipeline for gigantism and acromegaly treatment. Based on the acromegaly and gigantism drugs market insights, this market will register a CAGR of about 3% during the forecast period.
The demand for non-surgical options and the popularity of pharmacological therapies for acromegaly treatment is increasing on a regular basis due to the low success rate of acromegaly surgeries. According to our analysts, this is one of the key trends that will stimulate the growth of the acromegaly and gigantism drugs market size and share. It has been observed that only four of the 31 subjects treated by trans-sphenoidal surgery were cured. Additionally, post-operative anterior pituitary hormone deficiency was also observed in about 10 subjects. The preference of drug therapies for treating the disease will continue to increase due to the lack of skilled surgeons and pituitary surgical centers.
Top acromegaly and gigantism drugs companies covered in this market research report
The acromegaly and gigantism drugs market is moderately fragmented with companies focusing on developing new drugs. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, this acromegaly and gigantism drugs industry analysis report is designed to aid clients identify new growth opportunities and design innovative strategies for strengthening their position in the market.
The report offers a complete analysis of various companies including:
Acromegaly and gigantism drugs market segmentation based on geographic regions
The Americas will account for the highest market share throughout the forecast period. The Americas has always been a key market in the context of global acromegaly and gigantism drugs demand and this is mainly due to the high prevalence of the disease in the region.
Acromegaly and gigantism drugs market segmentation based on drug class
- Somatostatin analogs
- GH receptor antagonists
- Dopamine agonists
- Recombinant human IGF-1
The somatostatin analogs segment will account for the highest growth in the market. Additionally, the report will also provide an accurate prediction of the contribution of the various drug class segments to the growth of the acromegaly and gigantism drugs market size.
Key highlights of the global acromegaly and gigantism drugs market for the forecast years 2018-2022:
- CAGR of the market during the forecast period 2018-2022
- Detailed information on factors that will accelerate the growth of the acromegaly and gigantism drugs market during the next five years
- Precise estimation of the global acromegaly and gigantism drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- Growth of the acromegaly and gigantism drugs industry across the Americas, APAC, and EMEA
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details on the factors that will challenge the growth of the acromegaly and gigantism drugs companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
- Market outline
PART 05: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 06: MARKET SIZING
- Market definition
- Market sizing
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 08: PIPELINE ANALYSIS
PART 09: MARKET SEGMENTATION BY DRUG CLASS
- Segmentation by drug class
- Comparison by drug class
- Somatostatin analogs – Market size and forecast 2017-2022
- GH receptor antagonists – Market size and forecast 2017-2022
- Dopamine agonists – Market size and forecast 2017-2022
- Recombinant human IGF-1 – Market size and forecast 2017-2022
- Market opportunity by product
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas – Market size and forecast 2017-2022
- EMEA – Market size and forecast 2017-2022
- APAC – Market size and forecast 2017-2022
- Market opportunity
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 14: MARKET TRENDS
- Growing popularity of drugs over surgeries
- Focus on long-acting novel formulations
PART 15: VENDOR LANDSCAPE
- Landscape disruption
PART 16: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
PART 17: APPENDIX
- List of abbreviations
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get your FREE sample now!
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Did you know?
Did you know?
Did you know?
Want to customize this report?
This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.